- Home
- LXRX vs ACIU Comparison
LXRX vs ACIU Comparison
Compare LXRX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- ACIU
- Stock Information
- Founded
- LXRX 1995
- ACIU 2003
- Country
- LXRX United States
- ACIU Switzerland
- Employees
- LXRX N/A
- ACIU N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- ACIU Health Care
- Exchange
- LXRX Nasdaq
- ACIU Nasdaq
- Market Cap
- LXRX 283.7M
- ACIU 270.1M
- IPO Year
- LXRX 2000
- ACIU 2016
- Fundamental
- Price
- LXRX $0.71
- ACIU $2.65
- Analyst Decision
- LXRX Buy
- ACIU Strong Buy
- Analyst Count
- LXRX 2
- ACIU 2
- Target Price
- LXRX $4.00
- ACIU $12.00
- AVG Volume (30 Days)
- LXRX 4.1M
- ACIU 196.4K
- Earning Date
- LXRX 03-10-2025
- ACIU 03-13-2025
- Dividend Yield
- LXRX N/A
- ACIU N/A
- EPS Growth
- LXRX N/A
- ACIU N/A
- EPS
- LXRX N/A
- ACIU N/A
- Revenue
- LXRX $5,229,000.00
- ACIU $48,505,404.00
- Revenue This Year
- LXRX $842.94
- ACIU $86.78
- Revenue Next Year
- LXRX $19.76
- ACIU $118.22
- P/E Ratio
- LXRX N/A
- ACIU N/A
- Revenue Growth
- LXRX 886.60
- ACIU 4097200.00
- 52 Week Low
- LXRX $0.62
- ACIU $2.25
- 52 Week High
- LXRX $2.83
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- LXRX 43.33
- ACIU 47.51
- Support Level
- LXRX $0.66
- ACIU $2.39
- Resistance Level
- LXRX $0.97
- ACIU $2.74
- Average True Range (ATR)
- LXRX 0.07
- ACIU 0.14
- MACD
- LXRX -0.00
- ACIU 0.01
- Stochastic Oscillator
- LXRX 16.13
- ACIU 56.52
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.